Feb 18 (Reuters) – Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
The medical device maker also forecast full-year 2026 revenue growth of 20% to 22% in constant currency, with adjusted earnings per share expected to climb more than 25%.
For the current quarter, Insulet forecast 25% to 27% revenue growth in constant currency.
Insulet’s sales have surged following broader regulatory approvals for its Omnipod 5 automated insulin delivery system, a wearable device that attaches to the skin and is now cleared for use in both type 1 and type 2 diabetes patients in the United States.
Last week, Dexcom, Insulet’s larger peer, also reported robust demand for its continuous glucose monitoring systems.
Sales of Insulet’s Omnipod devices reached $781.8 million in the fourth quarter, above analysts’ estimate of $767.3 million according to data compiled by LSEG.
Insulet also announced a $350 million increase to its share repurchase authorization, with plans to deploy roughly $300 million in buybacks during the first quarter of 2026.
“(It is) a bullish signal on top of an already strong start to 2026 that should help support a positive response from investors today,” J.P.Morgan analyst Robbie Marcus said.
Total revenue jumped 31.2% to $783.8 million for the quarter ended December 31, compared with estimates of $768.7 million.
On an adjusted basis, Insulet earned $1.55 per share for the quarter, beating estimates of $1.45.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri)
Comments